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Acute myeloid leukaemia (AML) is the most common acute leukaemia affecting adults 
(Visser et al, 2012). Leukaemia stem cells (LSCs) have been shown to perpetuate AML 
(Bonnet & Dick, 1997), and Hedgehog signalling is involved in the maintenance of LSCs 
(Fukushima et al, 2016). Increased expression of the Hedgehog signalling target 
transcription factors GLI1 and GLI2 is associated with poor survival rate in AML and is 
correlated with the FLT3 mutation (Wellbrock et al, 2015). Results of a preclinical study 
showed that an inhibitor of the receptor Smoothened (SMO) could attenuate the 
leukaemia-initiating potential of AML cells and sensitise them to cytotoxic chemotherapy 
with cytarabine (Fukushima et al, 2016). In a phase I dose-finding study of glasdegib (PF-
04449913) in patients with myeloid malignancies, one of 28 patients with AML experienced 
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complete remission with incomplete blood count recovery, and four experienced partial 
remission with incomplete blood count recovery (Martinelli et al, 2015).  
 
Vismodegib is a Hedgehog pathway inhibitor (HPI) that binds to and inhibits SMO (Sekulic et 
al, 2012) and is currently approved for treatment of adults with metastatic or locally 
advanced basal cell carcinoma inappropriate for surgery or radiotherapy. We report here 
the results of a completed single-arm, open-label phase Ib study conducted to evaluate the 
safety and efficacy of vismodegib in adult patients with relapsed/refractory AML without 
prior HPI treatment. 
 
All patients recruited had relapsed/refractory AML; patients with acute promyelocytic 
leukaemia (M3 subtype) were excluded. Patients were stratified by poor-risk cytogenetics 
(per National Comprehensive Cancer Network guidelines [NCCN Guidelines®] for AML; 
O'Donnell et al, 2017), FLT3 mutations with intermediate-risk cytogenetics, or neither. 
Patients received vismodegib 150 mg orally, once daily until disease progression, intolerable 
toxicity or withdrawal of consent. Treatment interruption up to 14 days (before Week 8) or 
up to 4 weeks (after Week 8) was permitted to manage adverse events (AEs).  
 
A total of 47 patients were screened for enrolment from 12 study sites in Germany, Canada 
and the United States, and 38 received at least one dose of vismodegib between September 
2013 and September 2014, when the study was terminated by the sponsor because of lack 
of efficacy. Table I shows the baseline characteristics of the overall patient population by 
prognostic factor subgroup. All enrolled patients had received prior cancer therapy; most 
had received more than one therapy, including hypomethylating agents, 
immunomodulators and targeted signalling pathway inhibitors. At the end of the study (data 
cut-off 3 November 2014), all 38 patients had discontinued treatment with vismodegib, 19 
patients (50.0%) because of progressive disease (Supplementary Fig 1). The median follow-
up was 113·9 days (range 6–337 days).  
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Vismodegib treatment produced minimal clinical efficacy in patients with relapsed or 
refractory AML (Table II). Overall response rate comprised complete response (CR), CR with 
incomplete blood count recovery (CRi) or partial response (PR), and was 6.1% in the efficacy 
population. One patient experienced CRi at Day 57 (duration of response, 13 weeks) and 
one patient experienced PR at Day 26 (duration of response, 6 weeks); neither had poor-risk 
cytogenetics or FLT3-positive disease. The median duration of overall survival in all treated 
patients was 3·4 months (95% confidence interval [CI] 2·3–3·9); 33 patients died during the 
study, mainly because of disease progression (27 deaths). No deaths were considered 
related to vismodegib. 
 
In general, treatment with vismodegib was well-tolerated and most patients achieved a high 
cumulative dose intensity (median 99·6%; Table SI). Overall, 97·4% of patients experienced 
at least one AE on study (Table S2). The most common AEs were pyrexia, nausea, dysgeusia 
and epistaxis (Table S3). Alopecia, frequently associated with HPIs, occurred in 7·9% (three 
of 38) of patients overall. Grade ≥3 AEs were reported in 84·2% of patients overall. The most 
common of these were febrile neutropenia (21·1%), anaemia (15·8%), thrombocytopenia 
(15·8%), hyponatraemia (10·5%), hypoxia (10·5%), lung infection (10·5%) and pyrexia 
(10·5%). Serious AEs (SAEs) were reported in 26 (68·4%) patients (Table S4). Five patients 
(13·2%) experienced a total of six SAEs that were considered related to vismodegib: grade 3 
pyrexia (two cases), grade 2 oesophageal pain and grade 4 mucosal inflammation (both in 
one patient), ongoing grade 1 abdominal pain and grade 3 nausea (one case each). 
 
The AE profile was probably driven by patients’ underlying disease. The most common AEs 
are typical of patients with AML or are consistent with those seen in studies of vismodegib 
in patients with advanced basal cell carcinoma (BCC) (Lacouture et al, 2016). The most 
common SAEs and grade ≥3 AEs were infection and blood disorders, both of which are 
common in patients with relapsed or refractory AML, as is pyrexia. No new vismodegib 
safety signals were identified in this study. 
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In summary, vismodegib as a single agent produced minimal clinical efficacy in patients with 
relapsed/refractory AML, similar to other preliminary studies of HPI treatment in patients 
with myeloid malignancies with abnormal Hedgehog pathway signalling (Martinelli et al, 
2015; Tibes et al, 2015). Single-drug treatment is unlikely to produce significant durable 
responses in the absence of chemotherapy to clear the bulk leukaemia cell population 
(Pollyea et al, 2014). In the current study, detection of biomarkers of LSC response (e.g., 
changes in expression of Hedgehog ligands or target genes, such as GLI1 [Martinelli et al, 
2015], was not possible; therefore, an effect of vismodegib on LSCs cannot be ruled out. 
 
The two patients who responded were not FLT3 mutation positive. FLT3 mutation is 
associated with increased GLI1 and GLI2 expression and poor survival outcomes (Wellbrock 
et al, 2015). If the constitutive receptor tyrosine kinase activity of mutant FLT3 induces GLI 
transcription factor expression through cross-talk between signalling pathways, inhibiting 
Hedgehog signalling through SMO is unlikely to have an effect. Further investigation of 
combined targeted therapies may be warranted. 
 
For future studies, combination treatments that target the bulk leukaemia population and 
LSC-targeted therapy, such as HPIs, are more likely to show clinical benefit than LSC-
targeted agents alone. Given the role of Hedgehog signalling in maintaining LSCs, HPIs may 
be suited to maintenance therapy after induction of a response by chemotherapy.  
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Additional supporting information can be found in the online version of this article. 
Table SI. Study drug exposure in all treated patients. 
Table S2. Summary of adverse events occurring in all treated patients. 
Table S3. Adverse events of all grades occurring in ≥20% of all treated patients. 
Table S4. Serious adverse events occurring in ≥2 of all treated patients. 
Fig S1. Flow chart of patient disposition. 
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Table I. Baseline characteristics and demographics.  
Characteristic, n (%) Poor-risk 
cytogenetics 
n = 15 
FLT3-positive 
n = 4 
Neither 
n = 19 
All patients 
N = 38 
Men 9 (60·0) 2 (50·0) 10 (52·6) 21 (55·3) 
Women 6 (40·0) 2 (50·0) 9 (47·4) 17 (44·7) 
Age, median (range), years 67·0 (23–84) 55·0 (48–60) 72·0 (23–79) 68·5 (23–84) 
<60 years 4 (26·7) 3 (75·0) 4 (21·1) 11 (28·9) 
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≥60 years 11 (73·3) 1 (25·0) 15 (78·9) 27 (71·1) 
Race     
Asian 1 (6·7) 0 1 (5·3) 2 (5·3) 
Black/African American 1 (6·7) 0 1 (5·3) 2 (5·3) 
White 13 (86·7) 4 (100·0) 17 (89·5) 34 (89·5) 
Disease status at baseline  
a 
   
Primary refractory AML  9 (60·0) 1 (25·0) 5 (26·3) 15 (39·5) 
Relapsed AML  6 (40·0) 3 (75·0) 14 (73·7) 23 (60·5) 
AML, acute myeloid leukaemia. 
a
 
All enrolled patients had AML. 
Table II. Best overall response rates (all treated patients). 
Response, n (%) 
Poor-risk 
cytogenetics 
n = 15 
FLT3-positive 
n = 4 
Neither 
n = 19 
All patients 
N = 38 
Responders 0 0 2 (12·5) 2 (6·1) 
Non-responders 13 (100·0) 
a
 4 (100·0) 14 (87·5) 31 (93·9) 
95% CI for response rates 0·0–22·5 
b 
0·0–52·7 2·3–35·4 1·1–19·2 
CR [95% CI] 0 [0·0–22·5] 0 [0·0–52·7] 0 [0·0–19·8] 0 [0·0–9·2] 
CRi [95% CI] 0 [0·0–22·5] 0 [0·0–52·7] 
1 (6·3)  
[0·3–29·9] 
1 (3·0)  
[0·2–15·6] 
MLFS [95% CI] 0 [0·0–22·5] 0 [0·0–52·7] 0 [0·0–19·8] 0 [0·0–9·2] 
PR [95% CI] 0[0·0–22·5] 0 [0·0–52·7] 
1 (6·3) 
[0·3–29·9] 
1 (3·0)  
[0·2–15·6] 
CI, confidence interval; CR, complete response; CRi, complete response with incomplete 
blood count recovery; MLFS, morphological leukaemia-free state; NR, no response; PR, 
partial response. 
a
Patients classified as non-responders are patients without post-baseline progression and a 
response assessment within 8 weeks before treatment. 
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b
95% CIs for response rates were constructed using the Blyth-Still-Cassella method.  
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